GlobeNewswire: Relypsa, Inc. Contains the last 10 of 142 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T20:07:10ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2018/10/22/1624626/0/en/Relypsa-Announces-Presentation-of-New-Clinical-and-Real-World-Analyses-of-Veltassa-at-AMCP-Nexus-2018.html?f=22&fvtc=4&fvtv=20550 Relypsa Announces Presentation of New Clinical and Real-World Analyses of Veltassa® at AMCP Nexus 20182018-10-22T12:00:00Z<![CDATA[REDWOOD CITY, Calif., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Relypsa, Inc., a Vifor Pharma Group company, will present new data on Veltassa® (patiromer) at the Academy of Managed Care Pharmacy’s AMCP Nexus 2018 conference in Orlando, Florida, October 22-25. The new data reinforce the company’s commitment to understanding the real-world use and cost-effectiveness of Veltassa with the goal of improving the lives of patients with hyperkalemia or elevated blood potassium levels.]]>https://www.globenewswire.com/news-release/2018/10/09/1618849/0/en/Relypsa-Announces-Presentation-of-New-Clinical-and-Real-World-Analyses-of-Veltassa-at-ASN-Kidney-Week-2018.html?f=22&fvtc=4&fvtv=20550Relypsa Announces Presentation of New Clinical and Real-World Analyses of Veltassa® at ASN Kidney Week 20182018-10-09T20:00:00Z<![CDATA[REDWOOD CITY, Calif., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Relypsa, Inc., a Vifor Pharma Group company, will present new data on Veltassa® (patiromer) at the American Society of Nephrology (ASN) Kidney Week, the world’s premier nephrology meeting in San Diego, California, October 23-29. The new data reinforce the company’s commitment to improving the lives of patients with life-threatening conditions such as hyperkalemia–elevated blood potassium levels.]]>https://www.globenewswire.com/news-release/2018/10/01/1587708/0/en/Relypsa-Announces-Appointment-of-Patrick-Treanor-as-President.html?f=22&fvtc=4&fvtv=20550Relypsa Announces Appointment of Patrick Treanor as President2018-10-01T12:00:00Z<![CDATA[REDWOOD CITY, Calif., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Relypsa, Inc., a Vifor Pharma Group company, today announced the appointment of Patrick Treanor as president on an interim basis, effective October 1, 2018. Scott Garland has decided to step down as president to pursue other opportunities in the biotech sector.]]>https://www.globenewswire.com/news-release/2018/05/08/1498379/0/en/Relypsa-Announces-FDA-Approval-of-Supplemental-New-Drug-Application-to-Enable-the-Usage-of-Veltassa-patiromer-With-or-Without-Food.html?f=22&fvtc=4&fvtv=20550Relypsa Announces FDA Approval of Supplemental New Drug Application to Enable the Usage of Veltassa® (patiromer) With or Without Food2018-05-08T12:00:00Z<![CDATA[Updated label may allow for increased dosing flexibility for patients with hyperkalemia (elevated blood potassium) – a chronic, asymptomatic condition that often coexists with other disorders, including chronic kidney disease, heart failure, diabetes and/or high blood pressure Updated label may allow for increased dosing flexibility for patients with hyperkalemia (elevated blood potassium) – a chronic, asymptomatic condition that often coexists with other disorders, including chronic kidney disease, heart failure, diabetes and/or high blood pressure]]>https://www.globenewswire.com/news-release/2018/04/16/1472335/0/en/Relypsa-Funds-Three-Innovative-Research-Projects-on-Hyperkalemia-and-Associated-Disorders.html?f=22&fvtc=4&fvtv=20550Relypsa Funds Three Innovative Research Projects on Hyperkalemia and Associated Disorders2018-04-16T20:00:00Z<![CDATA[REDWOOD CITY, Calif., April 16, 2018 (GLOBE NEWSWIRE) -- Relypsa, Inc., a Vifor Pharma Group company, today announced that it has awarded three research grants to supplement institutional funding for nephrology and/or cardiology fellows pursuing a career in the area of hyperkalemia and associated disorders. Relypsa will fund the grant awards of up to $50,000 each for one academic year. Institutions receiving the research grants include the University of Cincinnati, Emory University and the University of Chicago.]]>https://www.globenewswire.com/news-release/2018/04/11/1468447/0/en/Relypsa-Presents-Patiromer-Clinical-Trial-Data-on-Serum-Potassium-in-Patients-with-Hyperkalemia-at-the-National-Kidney-Foundation-2018-Spring-Clinical-Meetings.html?f=22&fvtc=4&fvtv=20550Relypsa Presents Patiromer Clinical Trial Data on Serum Potassium in Patients with Hyperkalemia at the National Kidney Foundation 2018 Spring Clinical Meetings2018-04-11T12:00:00Z<![CDATA[Pooled Analysis of Three Phase 3 Studies Support Clinical Benefit and Use of Veltassa In Patients Who are on RAAS Inhibitor Therapy Pooled Analysis of Three Phase 3 Studies Support Clinical Benefit and Use of Veltassa In Patients Who are on RAAS Inhibitor Therapy]]>https://www.globenewswire.com/news-release/2017/11/03/1174726/0/en/Relypsa-Announces-Presentation-of-New-Clinical-and-Real-World-Analyses-of-Veltassa-at-ASN-Kidney-Week-2017.html?f=22&fvtc=4&fvtv=20550Relypsa Announces Presentation of New Clinical and Real-World Analyses of Veltassa® at ASN Kidney Week 20172017-11-03T21:30:00Z<![CDATA[REDWOOD CITY, Calif., Nov. 03, 2017 (GLOBE NEWSWIRE) -- Relypsa, Inc., a Vifor Pharma Group company, today announced results from a prespecified analysis of data from the Phase 4 TOURMALINE study of Veltassa® (patiromer) for oral suspension. The purpose of this analysis was to demonstrate the effect of treatment with this non-absorbed potassium binder on key markers of mineral metabolism, including calcium and phosphate. The findings were presented in an oral session at the American Society of Nephrology's (ASN) Kidney Week 2017, taking place October 31-November 5, in New Orleans. Two additional abstracts evaluating treatment with Veltassa in a real-world setting with patients on hemodialysis were presented yesterday in a poster session.]]>https://www.globenewswire.com/news-release/2017/07/21/1055661/0/en/Relypsa-Announces-European-Approval-of-Veltassa-to-Treat-Adult-Patients-with-Hyperkalemia-Elevated-Blood-Potassium-Levels.html?f=22&fvtc=4&fvtv=20550Relypsa Announces European Approval of Veltassa® to Treat Adult Patients with Hyperkalemia (Elevated Blood Potassium Levels)2017-07-21T12:00:00Z<![CDATA[REDWOOD CITY, Calif., July 21, 2017 (GLOBE NEWSWIRE) -- Relypsa, Inc., a Vifor Pharma Group company, today announced that the European Commission (EC) has approved the Marketing Authorization Application (MAA) for Veltassa® (patiromer) for the treatment of hyperkalemia, or elevated blood potassium levels. Veltassa, which is the brand name for patiromer in both the U.S. and Europe, is approved for marketing in all 28 EU countries and in Iceland, Liechtenstein and Norway. Vifor Pharma Group plans to launch Veltassa in Europe by the end of 2017 or in early 2018.]]>https://www.globenewswire.com/news-release/2017/04/19/962366/0/en/Relypsa-Presents-Veltassa-Phase-4-Data-Showing-Consistent-Efficacy-and-Safety-Whether-Taken-With-or-Without-Food-in-Patients-with-Hyperkalemia.html?f=22&fvtc=4&fvtv=20550Relypsa Presents Veltassa® Phase 4 Data Showing Consistent Efficacy and Safety Whether Taken With or Without Food in Patients with Hyperkalemia2017-04-19T22:00:00Z<![CDATA[REDWOOD CITY, Calif., April 19, 2017 (GLOBE NEWSWIRE) -- Relypsa, Inc., a Vifor Pharma Group company, today announced that data from its Phase 4 TOURMALINE study of the effect of Veltassa® (patiromer) for oral suspension on hyperkalemia when taken with or without food were presented in a poster session at the National Kidney Foundation (NKF) 2017 Spring Clinical Meetings in Orlando, Fla. Topline results from the TOURMALINE study were previously announced in August 2016.]]>https://www.globenewswire.com/news-release/2017/02/13/916681/0/en/Relypsa-Announces-Publication-of-Results-of-Veltassa-Drug-Drug-Interaction-Studies-in-Journal-of-Cardiovascular-Pharmacology-and-Therapeutics.html?f=22&fvtc=4&fvtv=20550Relypsa Announces Publication of Results of Veltassa Drug-Drug Interaction Studies in Journal of Cardiovascular Pharmacology and Therapeutics2017-02-13T21:30:00Z<![CDATA[REDWOOD CITY, Calif., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Relypsa, Inc., a Vifor Pharma company, today announced that results of drug-drug interaction studies of Veltassa® (patiromer) for oral suspension were published online by the Journal of Cardiovascular Pharmacology and Therapeutics. Results from 12 individual Phase 1 studies in healthy volunteers of 12 oral medications showed there were no clinically meaningful or statistically significant interactions between Veltassa and the 12 oral medications when taken at least three hours apart. Relypsa previously announced these findings in January 2016. ]]>